Keith Bragman

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

The Group's principal activity is the provision of technology solutions to the clinical trials industry. The Group's technology, services and products provide its customers, typically pharmaceutical and biotechnology companies, collects data and arrange clinical trials. These includes a range of consultancy, services and software. The Group's products includes ClinPhone Patient Recruitment, ClinPhone Randomisation, ClinPhone Trial Supply Management, ClinPhone ePRO, ClinPhone Clinical Trials Management Software, ClinPhone Drug Accountability, ClinPhone Integration Services and ClinPhone Trial Supply Simulation.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC.